Jordan Park

JPMorgan After Q4 - Cheap Relative to Earnings, But Watch Credit & Rates

Q4 beat on EPS, missed revenue; valuation looks attractive near $308, but policy and macro risks can reprice the stock quickly.

JPMorgan's Q4 print (01/13/2026) showed an EPS beat (5.23 vs 5.05 est.) but slightly softer revenue (45.80B vs 46.66B est.). At ~ $308.6 the shares tr...

Analyzing the Latest Movements in Palantir Technologies Stock

Technology Sector Downturn and Imminent Earnings Report Influence Palantir Shares

Palantir Technologies Inc. has experienced a decline in share price amid a broader market sell-off affecting technology stocks. As the company prepare...

Institutional Interest in BONK Signals Potential for Significant Price Increase Ahead of SHIB

Grayscale Investments’ inclusion of Solana-based BONK on its Assets Under Consideration list sparks speculation on institutional adoption and price trajectory

Grayscale Investments recently added BONK, a Solana-based meme coin, to its quarterly Assets Under Consideration (AUC) list. This marks the first time...

Understanding the Realities of Achieving Social Security's Maximum Benefit

The challenges behind maximizing monthly retirement payments and practical steps for enhancement

Social Security benefits for retirees vary widely, with most receiving around $2,000 monthly. While the maximum benefit can exceed $5,200, reaching th...

KULR Technology Group Advances with New Five-Year Battery Supply Partnership

Strategic agreement with Caban Energy positions KULR to expand presence in energy storage for critical infrastructure

KULR Technology Group has secured a five-year preferred battery supply contract with Caban Energy, a renewable energy services firm focusing on critic...

Citi CFO Highlights Risks of Credit Card Rate Caps After Mixed Q4 Results

Strong Interest Income and Investment Banking Growth Offset Revenue Miss and Russia Exit Charges

Citigroup reported a mixed fourth quarter with earnings surpassing forecasts but revenues falling short, impacted by divestitures related to its Russi...

ADMA Biologics: Why I’m Buying the Dip and My $26 Price Target

Plasma-derived margins are real, the balance sheet is stronger than headlines suggest, but legal and audit risk keep this a tactical, not a no-brainer, trade

ADMA Biologics (ADMA) is a commercial plasma biologics manufacturer showing expanding revenue, durable gross margins and positive operating cash flow....

MPLX: High Yield, Visible Distribution Growth, and a Reason to Buy on Pullbacks

Underappreciated cash flow + steady distribution hikes make MPLX an asymmetric income-growth trade for position investors

MPLX offers a compelling mix of an elevated yield (roughly 7% at current levels), visible distribution increases through 2025, and stable midstream ca...

Crypto Market Faces Extended Lull Despite Bitcoin and Ethereum Gains

Retail investors remain absent amid institutional-driven rallies, signaling a prolonged period of low engagement in cryptocurrencies

The cryptocurrency market, including notable spikes in Bitcoin and Ethereum prices, is exhibiting characteristics of a prolonged low-activity phase of...

The Market's Misdiagnosis on HealthEquity - A Swing Long With Defined Risk

Strong cash flow, steady revenues and improving operating leverage argue for upside from the mid-$80s; short-term legal noise and interest costs keep volatility high.

HealthEquity (HQY) is trading below where the fundamentals — consistent revenues (~$320M/quarter), expanding operating income and robust operating c...